Retinal Pigment Epithelium Cells ARPE-19 Transfection Kit

Description

AMD (Age-Related Macular Degeneration) is the leading cause of blindness worldwide. Research on the retinal pigment epithelium (RPE) cells has proven to be an ideal cell type for exploring new therapies for AMD. The retinal pigment epithelium (RPE) in the body is inaccessible. The RPE is located at the back of the eye, and its deterioration can lead to vision loss. The ARPE-19 cell line was established from the eye tissue of a 19-year-old male patient with AMD. These diploid cells exhibit epithelial cell morphology and morphological polarization under certain conditions. The study found that ARPE-19 cells can serve as transfection hosts in preclinical studies of cancers such as retinoblastoma and choroidal melanoma, and are critical in clinical studies. In order to facilitate in-depth research, a specific and efficient cell transfection system is essential. To this end, CD BioSciences has developed a specific transfection kit for the ARPE-19 cell line.